Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...

Ventyx Biosciences (NASDAQ:VTYX) announced Tuesday that a small mid-stage trial for VTX3232, its experimental therapy for Parkinson’s disease, reached the primary endpoint related to safety and ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The discussion also touched on Ventyx’s VTX3232, a CNS-penetrant NLRP3 inhibitor, with a Phase 2a readout for early Parkinson’s disease (PD) expected in June 2025. Additionally, ...

The company expects topline data throughout 2025, including the second quarter data from the VTX3232 study in early Parkinson's disease and H2 readouts from both the VTX2735 study in recurrent ...

Ventyx management has highlighted VTX3232’s strong safety and tolerability profile, which supports the potential for NLRP3 inhibitors across various high-value indications. According to InvestingPro ...